arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Lexeo Therapeutics, Inc.

LXEO

$4.80 ▲ +0.24 (+5.26%) at close

18 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Lexeo Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $389.7M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -7.6% ↘

FCF / Share $-0.26

Trailing P/E —

Price / Book 1.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-20.20M

↑ +38.2% —

FCF / Share Free cash flow per share

$-0.26

↑ +60.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	74.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	82.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	62.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	6.3% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	-28.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	92.8% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	92.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	93.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-19.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	38.2% Excellent ↑ Excellent Improving Year-over-year change in net income	19.3% Good ↑ Good Improving Year-over-year change in net income	-50.6% Weak ↑ Weak Improving Year-over-year change in net income	-50.6% Weak → Weak Stable Year-over-year change in net income	-50.6% Weak ↓ Weak Declining Year-over-year change in net income	-82.7% Weak ↓ Weak Declining Year-over-year change in net income	-16.2% Weak ↓ Weak Declining Year-over-year change in net income	-16.2% Weak ↑ Weak Improving Year-over-year change in net income	-16.2% Weak ↑ Weak Improving Year-over-year change in net income	2.7% Caution Caution Year-over-year change in net income	-49.2% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	60.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-21.9% Weak Weak Year-over-year change in free cash flow	—	—	—	95.3% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
FCF / Net Income (x)	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.09x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.14x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-7.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-14.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-17.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-30.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	9.8% Fair → Fair Stable Return earned on debt + equity capital invested Optimal: > 10%	7.7% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	11.6% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	10.6% Good Good Return earned on debt + equity capital invested Optimal: > 10%	14.0% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-8.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-15.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-10.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-10.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-37.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-15.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-8.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-158%)	-8.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-157%)	-27.0% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-280%)	-23.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-258%)	-37.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-347%)	-22.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-248%)	-15.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-204%)	-13.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-188%)	-11.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-179%)	-12.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-183%)	11.5% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-24%)	13.0% Fair → Fair Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-13%)	14.2% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-5%)	12.9% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-14%)	12.6% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-16%)	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	—	-672.86x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-629.49x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	—	-389.87x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-263.68x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-385.80x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-281.43x Weak Weak Operating income divided by interest expense Optimal: > 5x	-602.83x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-71.77M	$-63.00M	$-41.00M	$-35.48M	$-28.91M	$-35.01M	$-157.02M	$-174.98M	$-195.06M	$-121.47M	$-35.45M	—	—	$-77.33M	$-94.15M	—	$-135.86M	$-135.86M

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$0.32	—	—	—
Basic EPS, GAAP (USD)	$-0.25	$-0.14	$-0.33	$-0.60	$-0.99	$-0.78	$-0.89	$-0.64	$-0.77	$19.84	$-12.36	$-8.30	$-11.58	$-8.86	$-10.38	—	—	—
Free Cash Flow per Share (USD)	$-0.26	—	$-0.49	$-0.62	$-0.66	—	—	—	$-0.54	—	—	$-8.15	$-11.41	—	—	—	—	—
Book Value per Share (USD)	$3.12	$3.38	$2.20	$2.56	$2.65	$3.53	$4.21	$4.99	$5.56	$4.26	$-99.69	$-88.68	$-81.44	$-70.28	$-60.24	—	—	—
Tangible Book Value per Share (USD)	$3.12	$3.38	$2.20	$2.56	$2.65	$3.53	$4.21	$4.99	$5.56	$4.26	$-99.69	$-88.68	$-81.44	$-70.28	$-60.24	—	—	—
Basic Weighted Avg Shares (shares)	81.18M	—	60.98M	43.57M	33.11M	—	33.06M	33.00M	27.98M	—	1.63M	1.62M	1.61M	—	1.64M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$186.67M	$171.58M	$110.52M	$108.47M	$74.45M	$103.28M	$132.64M	$158.27M	$176.46M	$107.06M	$15.84M	—	—	$65.70M	—	—	—	—
Total Equity (USD)	$231.50M	$246.67M	$120.83M	$138.22M	$88.11M	$116.84M	$139.33M	$164.95M	$182.95M	$113.53M	$-162.81M	$-143.62M	$-131.18M	$-112.95M	$-98.98M	$-82.42M	$-55.60M	$-55.60M

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	$0.00	$531.00K	—	—	—
Net Income, GAAP (USD)	$-20.20M	$-20.92M	$-32.66M	$-32.66M	$-32.66M	$-25.92M	$-21.68M	$-21.68M	$-21.68M	$-14.19M	$-18.66M	$-18.66M	$-18.66M	$-14.58M	$-12.50M	—	—	—
Operating Cash Flow (USD)	$-21.14M	$-20.08M	$-29.55M	$-27.22M	$-21.72M	$-28.33M	—	—	$-14.87M	$-13.98M	—	$-13.19M	$-18.37M	$-16.63M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters

Lexeo Therapeutics, Inc.

Analytical Summary

18-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare LXEO with peers